y and products; our ability to successfully manufacture, market
and sell our products; the ability of Boston Scientific Corporation to
successfully manufacture, market and sell their paclitaxel-eluting coronary
stent products; the continued availability of capital to finance our
activities; our ability to achieve the financial benefits expected as a
result of the acquisition of American Medical Instruments Holdings, Inc.;
and any other factors referenced in our annual information form and other
filings with the applicable Canadian securities regulatory authorities or
Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
We disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained in this press release to reflect future results,
events or developments.
BSC acquired worldwide exclusive rights from Angiotech to use
paclitaxel to coat its coronary stent products and has co-exclusive rights
to certain peripheral vascular and non-vascular products.
(R) Registered trademarks of Boston Scientific Corporation
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
CONTACT: Deirdre Neary, Manager, Investor Relations, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, email@example.com
Page: 1 2 3 4 Related biology technology :1
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review2
. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day3
. Vical Names Andrew de Guttadauro Vice President, Corporate Development4
. Signalife Provides Corporate Update5
. Biomira Announces Plan to Reincorporate in the United States6
. Pressure BioSciences, Inc. Provides Corporate Update7
. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation8
. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters9
. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow10
. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated11
. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians